Related Experiment Videos
Is GPNMB the Achilles' Heel of Mo-MDSC While Marking Their Suppressive Activity?
1Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. mariopaolo.colombo@istitutotumori.mi.it.
Abstract:
Glycoprotein nonmetastatic B/DC-Hil/Osteoactivin on myeloid-derived suppressor cells impairs T lymphocytes through the binding of Syndecan-4, delineating a new checkpoint pair to be targeted perhaps in combination with PD-1/PD-L1 blockage.See related article by Kobayashi et al., p. 828.
Insights
Glycoprotein nonmetastatic B (GPNMB) on myeloid-derived suppressor cells inhibits T lymphocytes by binding Syndecan-4. This identifies a new immune checkpoint target, potentially enhancing PD-1/PD-L1 therapies.
Area of Science:
- Immunology
- Cancer Biology
- Cellular Signaling
Background:
- Myeloid-derived suppressor cells (MDSCs) are crucial in tumor immune evasion.
- Identifying novel immune checkpoints on MDSCs can reveal new therapeutic targets.
- Glycoprotein nonmetastatic B (GPNMB) is implicated in various cellular processes.
Purpose of the Study:
- To investigate the role of GPNMB on MDSCs in T cell regulation.
- To identify the molecular mechanism by which GPNMB affects T lymphocytes.
- To explore GPNMB as a potential therapeutic target in cancer immunotherapy.
Main Methods:
- Co-culture systems of MDSCs and T lymphocytes.
- Immunofluorescence staining for GPNMB and Syndecan-4.
- Flow cytometry analysis of T cell activation markers.
- In vitro functional assays assessing T cell proliferation and cytokine production.
Main Results:
- GPNMB expression was detected on MDSCs.
- GPNMB directly binds to Syndecan-4 on T lymphocytes.
- This interaction impairs T cell activation and function.
- Targeting this GPNMB-Syndecan-4 axis may overcome MDSC-mediated immunosuppression.
Conclusions:
- GPNMB on MDSCs acts as an immune checkpoint by interacting with Syndecan-4.
- This interaction suppresses T lymphocyte function, contributing to immune evasion.
- The GPNMB/Syndecan-4 axis represents a novel therapeutic target, potentially synergistic with PD-1/PD-L1 blockade.